Seborrhoeic dermatitis: current treatment practices

Bibliography

• UNNA PG: Notice. Monatschr Prakt. Dermatol (1891) 13:225–237.
   Google Scholar
• GUPTA A, BLUHM R: Seborrheic dermatitis." Ear. Acad. Dermatol Venereol (2004) 18(1):13–26.
   Google Scholar
• GUPTA AK, MADZIA SE, BATRA R: Etiology and management of Seborrheic dermatitis. Dermatology (2004) 208(2):89–93.
   PubMed Web of Science ®Google Scholar
• IVE FA, PAYNE R: Seborrhoeic dermatitis. In: Superficial fungal Infections. Verbov J (Ed.), MTP Press, Lancaster (1986):73–87.
   Google Scholar
• HAY RJ, GRAHAM-BROWN RA: Dandruff and seborrhoeic dermatitis: causes and management. Clin. Exp. Dermatol (1997) 22(1):3–6.
   PubMed Web of Science ®Google Scholar
• BURTON JL: Seborrheic dermatitis. In: Textbook of Dermatology Wilkinson DS, Ebling FJG (Eds), Blackwell Scientific Publications, Oxford, UK (1992):1561–1622.
   Google Scholar
• FAERGEMANN J: Seborrhoeic dermatitis and Pityrosporum orbiculare: treatment of seborrhoeic dermatitis of the scalp with miconazole-hydrocortisone (Daktacort), miconazole and hydrocortisone. Br. J. Dermatol (1986) 114(6):695–700.
   PubMed Web of Science ®Google Scholar
• FAERGEMANN J: Management of seborrheic dermatitis and pityriasis versicolor. Am. Clin. Dermatol (2000) 1(2):75–80.
   PubMedGoogle Scholar
• PIERARD-FRANCHIMONT C, HERMANNS JF, DEGREEF H, PIERARD GE: From axioms to new insights into dandruff. Dermatology (2000) 200(2):93–98.
   PubMed Web of Science ®Google Scholar
• FARTHING CF, STAUGHTON RC, ROWLAND PAYNE CM: Skin disease in homosexual patients with acquired immune deficiency syndrome (AIDS) and lesser forms of human T cell leukaemia virus (HTLV III) disease. Clin. Exp. Dermatol (1985) 10(1):3–12.
   PubMed Web of Science ®Google Scholar
• SMITH KJ, SKELTON HG, YEAGER J et al.: Cutaneous findings in HIV-1-positive patients: a 42-month prospective study. Military Medical Consortium for the Advancement of Retroviral Research (MMCARR). J. Am. Acad. Dermatol (1994) 31(5 Pt 1):746–754.
   Google Scholar
• MCCULLEY JP, DOUGHERTY JM, DENEAU DG: Classification of chronic blepharitis. Ophthalmology (1982) 89(10):1173–1180.
   PubMed Web of Science ®Google Scholar
• MCCULLEY JP, DOUGHERTY JM: Blepharitis associated with acne rosacea and seborrheic dermatitis. mt. Ophthalmol Clin. (1985) 25(1):159–172.
   PubMedGoogle Scholar
• REISNER RM: Acne vulgaris. Pediati: Clin North Am. (1973) 20(4):851–864.
   PubMed Web of Science ®Google Scholar
• ZUG KA, PALAY DA, ROCK B: Dermatologic diagnosis and treatment of itchy red eyelids. Surv Ophthalmol (1996) 40(4):293–306.
   PubMed Web of Science ®Google Scholar
• SABOURAUD R: Diagnosis and treatment of scalp disorders [in French]. (1932):156–169.
   Google Scholar
• SHUSTER S: The aetiology of dandruff and the mode of action of therapeutic agents. BE Dermatol (1984) 111(2):235–242.
   PubMed Web of Science ®Google Scholar
• ARRESE JE, PIERARD- FRANCHIMONT C, DE DONCKER P et al.: Effect of ketoconazole-medicated shampoos on squamometry and Malassezia ovalis load in pityriasis capitis. Cutts (1996) 58(3):235–237.
   Google Scholar
• HENG MC, HENDERSON CL, BARKER DC, HABERFELDE G: Correlation of Pityosporum ovale density with clinical severity of seborrheic dermatitis as assessed by a simplified technique. J. Am. Acad. Dermatol (1990) 23(1):82–86.
   PubMed Web of Science ®Google Scholar
• MCGINLEY KJ, LEYDEN JJ, MARPLES RR, KLIGMAN AM: Quantitative microbiology of the scalp in non-dandruff, dandruff, and seborrheic dermatitis. J. Invest. Dermatol (1975) 64(6):401–405.
   PubMed Web of Science ®Google Scholar
• EICHSTEDT E: Fungal structures in pityriasis vesicolor [in German]. Froriep Neue Notiz Natur Heilk (1846) 39:270.
   Google Scholar
• GUPTA AK, KOHLI Y, SUMMERBELL RC, FAERGEMANN J: Quantitative culture of Malassezia species from different body sites of individuals with or without dermatoses. Med. Mycol (2001) 39(3):243–251.
   PubMed Web of Science ®Google Scholar
• ••Determines quantity and composition ofMalassezia spp. at a given body site in normal individuals compared with patients with various cutaneous dermatoses.
   Google Scholar
• BERGBRANT IM, FAERGEMANN J: Seborrhoeic dermatitis and Pityrosporum ovale: a cultural and immunological study. Acta Derm. Venereol (1989) 69(4):332–335.
   PubMed Web of Science ®Google Scholar
• •Argues and supports the hypothesis that SD is caused by an inflammatory reaction to Malassezia spp., and that the quantity of the organism is of minor importance.
   Google Scholar
• BERGBRANT IM, JOHANSSON S, ROBBINS D et al: The evaluation of various methods and antigens for the detection of antibodies against Pityrosporum ovale in patients with seborrhoeic dermatitis. Clin. Exp. Dermatol (1991) 16(5):339–343.
   PubMed Web of Science ®Google Scholar
• BERGBRANT IM, JOHANSSON S, ROBBINS D et al: An immunological study in patients with seborrhoeic dermatitis. Clin. Exp. Dermatol (1991) 16(5):331–338.
   PubMed Web of Science ®Google Scholar
• KUPPER TS: The role of epidermal cytokines. In: Immunophysiology: the role of cells, and cytokines in immunity and inflammation. Shevach E, Oppenheim J (Eds), Oxford University Press, New York, USA (1990):285–305.
   Google Scholar
• •A good educational resource on SD immunophysiology.
   Google Scholar
• CATTERALL MD, WARD ME, JACOBS P: A reappraisal of the role of Pityrosporum orbiculare in pityriasis versicolor and the significance of extracellular lipase. Invest. Dermatol (1978) 71(6):398–401.
   PubMed Web of Science ®Google Scholar
• MID GLEY G, HAY RJ: Serological responses to Pityrosporum (Malassezia) in seborrhoeic dermatitis demonstrated by ELISA and western blotting. Bull. Soc. Fr. Mycol Med. (1988) 17:267–276.
   Google Scholar
• KIEFFER M, BERGBRANT IM, FAERGEMANN J et al: Immune reactions to Pityrosporum ovale in adult patients with atopic and seborrheic dermatitis." Am. Acad. Dermatol (1990) 22(5 Pt 1):739–742.
   Google Scholar
• ASHBEE HR, INGHAM E, HOLLAND KT, CUNLIFFE WJ: Cell-mediated immune responses to Malassezia furfur serovars A, B and C in patients with pityriasis versicolor, seborrheic dermatitis and controls. Exp. Dermatol (1994) 3(3):106–112.
   PubMedGoogle Scholar
• •Examines the cell-mediated immune responses to various M furfurserovars.
   Google Scholar
• NEUBER K, KROGER S, GRUSECK E, ABECK D, RING J: Effects of Pityrosporum ovale on proliferation, immunoglobulin (IgA, G, M) synthesis and cytokine (IL-2, IL-10, IFN gamma) production of peripheral blood mononuclear cells from patients with seborrhoeic dermatitis. Arch. Dermatol Res. (1996) 288(9):532–536.
   PubMed Web of Science ®Google Scholar
• •Supports the hypothesis that skin colonisation with M furfarin SD is due to an altered cellular immunity, which may be induced by increased IL-10 secretion.
   Google Scholar
• PARRY ME, SHARPE GR: Seborrhoeic dermatitis is not caused by an altered immune response to Malassezia yeast. Br. .1. Dermatol (1998) 139(2):254–263.
   Google Scholar
• •Presents arguments against the hypothesis that an inadequate immune response to Malassezia yeast could lead to SD.
   Google Scholar
• BERGBRANT IM: Seborrhoeic dermatitis and Pityrosporum ovale: cultural, immunological and clinical studies. Acta Berm. Venereol Sapp] (Stockh) (1991) 167:1–36.
   PubMedGoogle Scholar
• •Examines the density of Malassezia in SD and how it changes with age, the immunological functions in patients with SD, and evaluates methods of detecting antibodies against M furfin:
   Google Scholar
• HALE EK, BYSTRYN JC: Relation between skin temperature and location of facial lesions in seborrheic dermatitis. Arch. Dermatol (2000) 136(4):559–560.
   PubMedGoogle Scholar
• REBORA A, RONGIOLETTI F: The red face: seborrheic dermatitis. Clin. Dermatol (1993) 11(2):243–251.
   PubMed Web of Science ®Google Scholar
• PECHERE M, KRISCHER J, REMONDAT C et al.: Malassezia spp carriage in patients with seborrheic dermatitis. J. Dermatol (1999) 26(9):558–561.
   PubMedGoogle Scholar
• PIERARD-FRANCHIMONT C, WILLEMAERS V, FRAITURE AL, PIERARD GE: Squamometry in seborrheic dermatitis. Int. J. Dermatol (1999) 38(9):712–715.
   PubMed Web of Science ®Google Scholar
• SHEMER A, NATHANSOHN N, KAPLAN B et al.: Treatment of scalp seborrheic dermatitis and psoriasis with an ointment of 40% urea and 1% bifonazole. Int. J. Dermatol (2000) 39(7):532–534.
   PubMed Web of Science ®Google Scholar
• ABECK D: Rationale of frequency of use of ciclopirox 1% shampoo in the treatment of seborrheic dermatitis: results of adouble-blind, placebo-controlled study comparing the efficacy of once, twice, and three times weekly usage. Int. .1. Dermatol (2004) (In Press).
   Google Scholar
• JUE SG, DAWSON GW, BROGDEN RN: Ciclopirox olamine 1% cream. A preliminary review of its antimicrobial activity and therapeutic use. Drugs (1985) 29(4):330–341.
   Google Scholar
• KORTING HC, GRUNDMANN-KOLLMANN M: The hydroxypyridones: a class of antimycotics of its own. Mycoses (1997) 40(7-8):243–247.
   PubMed Web of Science ®Google Scholar
• UNHOLZER A, VARIGOS G, NICHOLLS D et al.: Ciclopiroxolamine cream for treating seborrheic dermatitis: a double-blind parallel group comparison. Infection (2002) 30(6):373–376.
   PubMed Web of Science ®Google Scholar
• ••A well conducted and reported clinicaltrial.
   Google Scholar
• ABDEL-RAHMAN SM, NAHATA MC: Oral terbinafine: a new antifungal agent. Ann. Pharmacother (1997) 31(4):445–456.
   PubMed Web of Science ®Google Scholar
• FAERGEMANN J: Treatment of seborrhoeic dermatitis with oral terbinafine? Lancet (2001) 358(9277):170.
   PubMed Web of Science ®Google Scholar
• FOURNIER J, EMERIT J, MICHELSON AM: [Peroxidation of lipids in the inflammatory process]. C. R. Seances Acad. Sci. D. (1980) 291(9):753–755.
   PubMedGoogle Scholar
• MARKS R, PEARSE AD, WALKER AP: The effects of a shampoo containing zinc pyrithione on the control of dandruff. Br. J. Dermatol (1985) 112(4):415–422.
   PubMed Web of Science ®Google Scholar
• SCHMID MH, KORTING HC: Coal tar, pine tar and sulfonated shale oil preparations: comparative activity, efficacy and safety. Dermatology (1996) 193(1):1–5.
   PubMed Web of Science ®Google Scholar
• MCGRATH J, MURPHY GM: The control of seborrhoeic dermatitis and dandruff by antipityrosporal drugs. Drugs (1991) 41(2):178–184.
   PubMed Web of Science ®Google Scholar
• PIERARD-FRANCHIMONT C, GOFFIN V, DECROIX J, PIERARD GE: A multicenter randomized trial of ketoconazole 2% and zinc pyrithione 1% shampoos in severe dandruff and seborrheic dermatitis. Skin Pharmacol Appl Skin Physiol (2002) 15(6):434–441.
   PubMedGoogle Scholar
• ••A well conducted and reported clinicaltrial.
   Google Scholar
• PIERARD-FRANCHIMONT C, PIERARD GE: A double-blind placebo-controlled study of ketoconazole + desonide gel combination in the treatment of facial seborrheic dermatitis. Dermatology (2002) 204(4):344–347.
   PubMed Web of Science ®Google Scholar
• ERMOLAYEVA E, SANDERS D: Mechanism of pyrithione-induced membrane depolarization in Neurospora crassa. Appl. Environ. Microbiol (1995) 61(9):3385–3390.
   PubMed Web of Science ®Google Scholar
• LACKNER TE, CLISSOLD SP: Bifonazole. A review of its antimicrobial activity and therapeutic use in superficial mycoses. Drugs (1989) 38(2):204–225.
   Google Scholar
• HEGEMANN L, TOSO SM, LAHIJANI KI, WEBSTER GF, UITTO J: Direct interaction of antifungal azole-derivatives with calmodulin: a possible mechanism for their therapeutic activity. J. Invest. Dermatol (1993) 100(3):343–346.
   PubMed Web of Science ®Google Scholar
• •A well conducted and reported clinical trial.
   Google Scholar
• BREMM KD, PLEMPEL M: Modulation of leukotriene metabolism from human polymorphonuclear granulocytes by bifonazole. Mycoses (1991) 34(1-2):41–45.
   PubMed Web of Science ®Google Scholar
• VAN ERP PE, VAN DE KERKHOF PC: Calmodulin levels in psoriasis and other skin disorders. Arch. Dermatol Res. (1987) 279(3):151–153.
   PubMed Web of Science ®Google Scholar
• HAGEMANN I, PROKSCH E: Topical treatment by urea reduces epidermal hyperproliferation and induces differentiation in psoriasis. Acta Berm. Venereol (1996) 76(5):353–356.
   PubMed Web of Science ®Google Scholar
• KUSTER W, BOHNSACK K, RIPPKE F et al.: Efficacy of urea therapy in children with ichthyosis. A multicenter randomized, placebo-controlled, double-blind, semilateral study. Dermatology (1998) 196(2):217–222.
   Google Scholar
• WOHLRAB W: The influence of urea on the penetration kinetics of topically applied corticosteroids. Acta Berm. Venereol (1984) 64(3):233–238.
   PubMed Web of Science ®Google Scholar
• PARSAD D, PANDHI R, NEGI KS, KUMAR B: Topical metronidazole in seborrheic dermatitis-a double-blind study. Dermatology (2001) 202(1):35–37.
   PubMed Web of Science ®Google Scholar
• KOCA R, ALTINYAZAR HC, ESTURK E: Is topical metronidazole effective in seborrheic dermatitis? A double-blind study. Int. J. Dermatol (2003) 42(8):632–635.
   PubMed Web of Science ®Google Scholar
• CAMERA E, CANNISTRACI C, BRIGANTI S, COLOMBO D, PICARDO M: Scavenging effects of terbinafine on free radicals in vitro. Br. J. Dermatol (1999) 140(4):640–644.
   PubMed Web of Science ®Google Scholar
• ROSEN T, SCHELL BJ, ORENGO I: Anti-inflammatory activity of antifungal preparation. Int. J. Dermatol (1997) 36(10):788–792.
   PubMed Web of Science ®Google Scholar
• COWLEY NC, FARR PM, SHUSTER S: The permissive effect of sebum in seborrhoeic dermatitis: an explanation of the rash in neurological disorders. Br. J. Dermatol (1990) 122(1):71–76.
   PubMed Web of Science ®Google Scholar
• CORTE M, JUNG K, LINKER U et al: [Topical application of a 0.1% ciclopiroxolamine solution for the treatment of pityriasis versicolor]. Mycoses (1989) 32(4):200–203.
   Google Scholar
• HANEL H, SMITH-KURTZ E, PASTOWSKY S: [Therapy of seborrheic eczema with an antifungal agent with an antiphlogistic effect]. Mycoses (1991) 34\(Suppl. 1):91–93.
   Google Scholar
• GOUDARD M, REGLI P, LUBRANO N: [In vitro antifungal spectrum of ciclopiroxolamine]. Pathol Biol. (Paris) (1989) 37(5 Pt 2):621–623.
   Google Scholar
• SQUIRE RA, GOODE K: A randomised, single-blind, single-centre clinical trial to evaluate comparative clinical efficacy of shampoos containing ciclopirox olamine (1.5%) and salicylic acid (3%), or ketoconazole (2%, Nizoral) for the treatment of dandruff/seborrhoeic dermatitis. J. Dermatolog. Treat. (2002) 13(2):51–60.
   Google Scholar
• ALY R, KATZ HI, KEMPERS SE et al: Ciclopirox gel for seborrheic dermatitis of the scalp. Int. J. Dermatol (2003) 42\(Suppl. 1):19–22.
   Google Scholar
• ALTMEYER P: Efficacy of different concentrations of ciclopirox shampoo for the treatment of seborrheic dermatits of the scalp: results of a randomized, double blind, vehicle-controlled trial. Int. .1. Dermatol (2004) (In Press).
   Google Scholar
• LEBWOHL M, PLOTT T: Safety and efficacy of cilcopirox 1% shampoo for the treatment of seborrheic dermatitis of the scalp in the US population: results of a double-blind, vehicle-controlled trial. Int .1. Dermatol (2004) (In Press).
   Google Scholar
• FORD GP, FARR PM, IVE FA, SHUSTER S: The response of seborrhoeic dermatitis to ketoconazole. Br .1. Dermatol (1984) 111(5):603–607.
   Google Scholar
• SEHGAL VN, KHANDPUR S: Antifungal agents: unapproved uses, dosages, or indications. Clin. Dermatol (2002) 20(5):481–489.
   PubMed Web of Science ®Google Scholar
• LEEMING JP, SANSOM JE, BURTON JL: Susceptibility of Malassezia furfur subgroups to terbinafine. Br J. Dermatol (1997) 137(5):764–767.
   PubMed Web of Science ®Google Scholar
• VILLARS VV, JONES TC: Special features of the clinical use of oral terbinafine in the treatment of fungal diseases. Br. .1. Dermatol (1992) 126\(Suppl. 39):61–69.
   Google Scholar
• GUPTA AK, KOHLI Y: In vitro susceptibility testing of ciclopirox, terbinafine, ketoconazole and itraconazole against dermatophytes and nondermatophytes, and in vitro evaluation of combination antifungal activity. Br. J. Dermatol (2003) 149(2):296–305.
   PubMed Web of Science ®Google Scholar
• FREEMAN S, HOWARD A, FOLEY P et al.: Efficacy, cutaneous tolerance and cosmetic acceptability of desonide 0.05% lotion (Desowen) versus vehicle in the short-term treatment of facial atopic or seborrhoeic dermatitis. Australas. Dermatol (2002) 43(3):186–189. A well conducted and reported clinical trial.
   Google Scholar
• FRANZ TJ, PARSELL DA, HALUALANI RIVI et al: Betamethasone valerate foam 0.12%: a novel vehicle with enhanced delivery and efficacy. Int. J. Dermatol (1999) 38(8):628–632.
   Google Scholar
• CHRISTODOULOU GN, GEORGALA S, VARELTZIDES A, CATSAROU A: Lithium in seborrheic dermatitis. Psych/atr.j Univ Ott. (1983) 8(1):27–29.
   PubMedGoogle Scholar
• EFALITH MULTICENTER TRIAL GROUP: A double-blind, placebo-controlled, multicenter trial of lithium succinate ointment in the treatment of seborrheic dermatitis. J. Am. Acad. Dermatol (1992) 26(3 Pt 2):452–457. ao. DRENO B, MOYSE D: Lithium gluconate in the treatment of seborrhoeic dermatitis: a multicenter, randomised, double-blind study versus placebo. Eur. j Dermatol (2002) 12(6):549–552.
   Google Scholar
• ••A well conducted and reported clinicaltrial.
   Google Scholar
• SCAPARRO E, QUADRI G, VIRNO G, ORIFICI C, MILANI M: Evaluation of the efficacy and tolerability of oral terbinafine (Daskil) in patients with seborrhoeic dermatitis. A multicentre, randomized, investigator-blinded, placebo-controlled trial. Br. J. Dermatol (2001) 144(4):854–857.
   Google Scholar
• LEEMING JP, BURTON JL: Lithium succinate and seborrhoeic dermatitis: an antifungal mode of action? Br. J. Dermatol (1990) 122(5):718–719.
   Web of Science ®Google Scholar
• NENOFF P, HAUSTEIN UF, MUNZBERGER C: In vitro activity of lithium succinate against Malassezia furfur. Dermatology (1995) 190(1):48–50.
   PubMed Web of Science ®Google Scholar
• HORROBIN DF: Effects of lithium on essential fatty acid and prostaglandin metabolism. In: Lithium and cell physiology Springer-Verlog, New York, USA (1990):137–49.
   Google Scholar
• MAES M, SONG C, LIN AH et al: In vitro immunoregulatory effects of lithium in healthy volunteers. Psychopharmacology (Ben) (1999) 143(4):401–407.
   PubMed Web of Science ®Google Scholar
• OCKENFELS HM, WAGNER SN, KEIM-MAAS C et al.: Lithium and psoriasis: cytokine modulation of cultured lymphocytes and psoriatic keratinocytes by lithium. Arch. Dermatol Res (1996) 288(4):173–178.
   PubMed Web of Science ®Google Scholar
• DRENO B, CHOSIDOW O, REVUZ J, MOYSE D: Lithium gluconate 8% versus ketoconazole 2% in the treatment of seborrhoeic dermatitis: a multicentre, randomized study. Br. J. Dermatol (2003) 148(6):1230–1236.
   PubMed Web of Science ®Google Scholar
• CRUTCHFIELD CE, III: Pimecrolimus: a new treatment for seborrheic dermatitis. Culls (2002) 70(4) :207–208.
   Google Scholar
• BROWNELL I, QUAN LT, HSU S: Topical pimecrolimus in the treatment of seborrheic dermatitis. Dermatol Online J. (2003) 9(3):13.
   PubMedGoogle Scholar
• BORNHOVD E, BURGDORF WH, WOLLENBERG A: Macrolactam immunomodulators for topical treatment of inflammatory skin diseases. J. Am. Acad. Dermatol (2001) 45(5):736–743.
   PubMed Web of Science ®Google Scholar
• LEMSTER BH, CARROLL PB, RILO HR et al.: IL-8/IL-8 receptor expression in psoriasis and the response to systemic tacrolimus (FK506) therapy. Clin. Exp. Immunol (1995) 99(2):148–154.
   PubMed Web of Science ®Google Scholar
• MORI A, SUKO M, NISHIZAKI Y et al: Regulation of interleukin-5 production by peripheral blood mononuclear cells from atopic patients with FK506, cyclosporin A and glucocorticoid. Int. Arch. Allergy Immunol (1994) 104\(Suppl. 1):32–35.
   Google Scholar
• NAKAGAWA H, ETOH T, ISHIBASHI Y et al.: Tacrolimus ointment for atopic dermatitis. Lancet (1994) 344(8926):883.
   PubMed Web of Science ®Google Scholar
• RUZICKA T, BIEBER T, SCHOPF E et al.: A short-term trial of tacrolimus ointment for atopic dermatitis. European Tacrolimus Multicenter Atopic Dermatitis Study Group. N Engl I Med. (1997) 337(12):816–821.
   Google Scholar
• MEINGASSNERJG, STUTZ A: Immunosuppressive macrolides of the type FK 506: a novel class of topical agents for treatment of skin diseases? J. Invest. Dermatol (1992) 98(6):851–855.
   PubMed Web of Science ®Google Scholar
• SENGOKU T, MORITA K, SATO S et al: [Effects of tacrolimus ointment on Type I (immediate and late) and IV (delayed) cutaneous allergic reactions in mice]. Nippon Yakurigaku Zasshi (1998) 112(3):221–232.
   PubMedGoogle Scholar
• KRAGBALLE K, GJERTSEN BT, DE HOOP D et al.: Double-blind, right/left comparison of calcipotriol and betamethasone valerate in treatment o psoriasis vulgaris. Lancet (1991) 337(8735):193–196.
   Google Scholar
• BERTH-JONES J, HUTCHINSON PE: Vitamin D analogues and psoriasis. Br. J. Dermatol (1992) 127(2):71–78.
   PubMed Web of Science ®Google Scholar
• JENSEN AM, LLADO MB, SKOV L et al:Calcipotriol inhibits the proliferation of hyperproliferative CD29 positive keratinocytes in psoriatic epidermis in the absence of an effect on the function and number of antigen-presenting cells. Br. J. Dermatol (1998) 139(6):984–991. loft KRAGBALLE K, IVERSEN L: Calcipotriol. A new topical antipsoriatic. Dermatol Clin. (1993) 11(1):137–141.
   Google Scholar
• BASAK PY, ERGIN S: Comparative effects of calcipotriol and betamethasone 17-valerate solution in the treatment of seborrhoeic dermatitis of the scalp. Lid. Acad. Dermatol Venereol (2001) 15(1):86–88.
   PubMed Web of Science ®Google Scholar
• DE MARE S, DE JONG EG, VAN DE KERKHOF PC: DNA content and Ks8.12 binding of the psoriatic lesion during treatment with the vitamin D3 analogue MC903 and betamethasone. Dermatol (1990) 123(3):291–295.
   Google Scholar
• BERG M: Epidemiological studies of the influence of sunlight on the skin. Photodermatology (1989) 6(2):80–84.
   PubMedGoogle Scholar
• DAHL KB, REYMANN F: Photochemotherapy in erythrodermic seborrhoic dermatitis. Arch. Dermatol (1977) 113(9):1295–1296.
   PubMedGoogle Scholar
• SALO O, LASSUS A, JUVAKOSKI T, KANERVA L, LAUHARANTA J: [Treatment of atopic dermatitis and seborrheic dermatitis with selective UV-phototherapy and PUVA. A comparative study]. Dermatol Monatsschr (1983) 169(6):371–375.
   PubMedGoogle Scholar
• DUTHIE MS, KIMBER I, NORVAL M: The effects of ultraviolet radiation on the human immune system. Br. j Dermatol (1999) 140(6):995–1009.
   PubMed Web of Science ®Google Scholar
• EL GHORR AA, NORVAL M: Biological effects of narrow-band (311 nm TL01) UVB irradiation: a review. J. Photochem. Photobiol B(1997) 38(2-3):99–106.
   PubMed Web of Science ®Google Scholar
• VIAC J, GOUJON C, MISERY L et al.: Effect of UVB 311 nm irradiation on normal human skin. Photodermatol Photoimmunol Photomed. (1997) 13(3):103–108.
   PubMed Web of Science ®Google Scholar
• MOEHRLE M, DENNENMOSER B, SCHLAGENHAUFF B, THOMMA S, GARBE C: High prevalence of seborrhoeic dermatitis on the face and scalp in mountain guides. Dermatology (2000) 201(2):146–147.
   PubMed Web of Science ®Google Scholar
• PETER RU, RI CHARZ-BARTHAUER U: Successful treatment and prophylaxis of scalp seborrhoeic dermatitis and dandruff with 2% ketoconazole shampoo: results of a multicentre, double-blind, placebo-controlled trial. Br. J. Dermatol (1995) 132(3):441–445.
   PubMed Web of Science ®Google Scholar
• ••A well conducted and reported clinicaltrial.
   Google Scholar
• SKINNER RB, JR., NOAH PW, TAYLOR RM et al.: Double-blind treatment of seborrheic dermatitis with 2% ketoconazole cream. J. Am. Acad. Dermatol (1985) 12(5 Pt 1):852–856.
   Google Scholar
• STRATIGOS JD, ANTONIOU C, KATSAMBAS A et al.: Ketoconazole 2% cream versus hydrocortisone 1% cream in the treatment of seborrheic dermatitis. A double-blind comparative study. J. Am. Acad. Dermatol (1988) 19(5 Pt 1):850–853.
   Google Scholar
• FAERGEMANN J: Treatment of seborrhoeic dermatitis of the scalp with ketoconazole shampoo. A double-blind study. Acta Derm. Venereol (1990) 70(2):171–172.
   PubMed Web of Science ®Google Scholar
• DUPUY P, MAURETTE C, AMORIC JC, CHOSIDOW O: Randomized, placebo-controlled, double-blind study on clinical efficacy of ciclopiroxolamine 1% cream in facial seborrhoeic dermatitis. Br. Dermatol (2001) 144(5):1033–1037.
   PubMed Web of Science ®Google Scholar
• ••A well conducted and reported clinicaltrial.
   Google Scholar
• CHOSIDOW O, MAURETTE C, DUPUY P: Randomized, open-labeled, non-inferiority study between ciclopiroxolamine 1% cream and ketoconazole 2% foaming gel in mild to moderate facial seborrheic dermatitis. Dermatology (2003) 206(3):233–240.
   PubMed Web of Science ®Google Scholar
• ••A well conducted and reported clinicaltrial.
   Google Scholar
• BAYSAL V, YILDIRIM M, OZCANLI C, CEYHAN AM: Itraconazole in the treatment of seborrheic dermatitis: a new treatment modality. mt. .1 Dermatol (2004) 43(1):63–66.
   Google Scholar
• CAPUTO R, BARBARESCHI M: Itraconazole: new horizons. Giornale Itlaiano di dermatologia e venereologia. Giornale Itlaiano di dermatologiae venereologia (2002) 137:1–7.
   Google Scholar
• CASSANO NMD, AMORUSO AMD, LOCONSOLE FMD, VENA GAMD: Oral terbinafine for the treatment of seborrheic dermatitis in adults. Int. Dermatol (2002) 41(11):821–822.
   PubMed Web of Science ®Google Scholar
• MILANI M, ANTONIO DM, GRAMAZIO R et al.: Efficacy of betamethasone valerate 0.1% thermophobic foam in seborrhoeic dermatitis of the scalp: an open-label, multicentre, prospective trial on 180 patients. Curi: Med. Res. Opin (2003) 19(4):342–345.
   Google Scholar
• MESHKINPOUR A, SUN J, WEINSTEIN G: An open pilot study using tacrolimus ointment in the treatment of seborrheic dermatitis. J. Am. Acad. Dermatol (2003) 49(1):145–147.
   PubMed Web of Science ®Google Scholar
• BRAZA TJ, DICARLO JB, SOON SL, MCCALL CO: Tacrolimus 0.1% ointment for seborrhoeic dermatitis: an open-label pilot study. Br. Dermatol (2003) 148(6):1242–1244.
   Google Scholar
• BERTH-JONES J, ADNITT PI: Topical calcipotriol is not effective in facial seborrhoeic dermatitis. .1 Dermatolog. Treat. (2001) 12(3):179.
   Google Scholar